KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/ Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia
Publication
, Conference
Zeidan, A; Fathi, A; Issa, G; Erba, H; Ahsan, JM; Corum, D; Tomkinson, B; Kozlek, T; Leoni, M; Wang, E
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2023
Duke Scholars
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
2023
Volume
23
Start / End Page
S308 / S309
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Zeidan, A., Fathi, A., Issa, G., Erba, H., Ahsan, J. M., Corum, D., … Wang, E. (2023). KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/ Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 23, pp. S308–S309).
Zeidan, Amer, Amir Fathi, Ghayas Issa, Harry Erba, Julie Mackey Ahsan, Daniel Corum, Blake Tomkinson, Tom Kozlek, Mollie Leoni, and Eunice Wang. “KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/ Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23:S308–9, 2023.
Zeidan A, Fathi A, Issa G, Erba H, Ahsan JM, Corum D, et al. KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/ Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S308–9.
Zeidan, Amer, et al. “KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/ Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 23, 2023, pp. S308–09.
Zeidan A, Fathi A, Issa G, Erba H, Ahsan JM, Corum D, Tomkinson B, Kozlek T, Leoni M, Wang E. KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/ Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S308–S309.
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
2023
Volume
23
Start / End Page
S308 / S309
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences